Keiko Yanagihara^1,*, Masato Yoshida², Kensaku Awaji², Tamami Yamakawa¹, Sena Kato¹, Miki Tamura¹, Koji Nagata³

Oncology Research, Vol.34, No.1, 2026, DOI:10.32604/or.2025.073891 - 30 December 2025

Abstract Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have transformed the management of hormone receptor–positive/HER2–negative (HR+/HER2–) advanced breast cancer, yet evidence for elderly or poor-performance patients remains limited. This study examined real-world outcomes of palbociclib plus endocrine therapy in Asian patients, with additional subgroup analyses by age and performance status. Methods: We retrospectively analyzed 46 consecutive Asian patients with recurrent or de novo HR+/HER2− breast cancer treated with first-line palbociclib plus ET between April 2021 and March 2025. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), disease control rate (DCR), and safety.… More >

Marie Chaumel¹, Nicolas Brichart², Franck Bruyère¹, Ali Bourgi^1,*

Canadian Journal of Urology, Vol.32, No.4, pp. 359-366, 2025, DOI:10.32604/cju.2025.066470 - 29 August 2025

Abstract Background: The COVID-19 pandemic disrupted healthcare systems globally, raising concerns about delayed cancer diagnosis and treatment. In France, transurethral resection of bladder tumors (TURBT) was prioritized in national urology guidelines to ensure the timely management of urothelial carcinoma. This study aimed to assess the impact of care reorganization on tumor staging, recurrence, palliative care, and mortality in bladder cancer patients from the pre-pandemic through late-pandemic periods. Methods: We conducted a retrospective multicenter study including all patients who underwent TURBT with histologically confirmed urothelial carcinoma between April and December of 2019 (pre-pandemic), 2020 (early pandemic), 2021… More >

Xi Qin^1,#, Yulan Liu^1,#, Lin Zhu², Yunyan Mo¹, Jing Zhang³, Zhuchun Jiang⁴, Dongning Huang⁵, Xinrong Hu⁶, Jingzhang Li⁷, Quanfang Chen⁸, Feng Xue^1,*

Oncology Research, Vol.33, No.9, pp. 2451-2462, 2025, DOI:10.32604/or.2025.064119 - 28 August 2025

Abstract Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events… More >

Junxing Chen^1,#, Luping Pan^1,#, Yunzhi Liu^1,2, Yan Fang¹, Ruoxuan Li¹, Zhiqin Lu^1,3, Anwen Liu^1,4, Yanqing He^5,*, Zhimin Zeng^1,6,*

Oncology Research, Vol.33, No.8, pp. 2107-2121, 2025, DOI:10.32604/or.2025.064237 - 18 July 2025

Abstract Background: Non-small cell lung cancer (NSCLC) patients with leptomeningeal metastasis (LM) have a very poor prognosis. Intrathecal pemetrexed (IP) has shown moderate efficacy in treating patients with NSCLC-LM. Myelosuppression is the most common adverse effect following IP administration. Despite this trend, the specific risk factors contributing to IP-related myelosuppression remain unclear. Methods: This study conducted a retrospective analysis of lung adenocarcinoma (LUAD) patients with LM who received IP treatment at the Second Affiliated Hospital of Nanchang University from April 2017 to April 2024. Risk factors for myelosuppression were identified through univariate and multivariate logistic regression… More >

Yushen Fang¹, Zechen Li¹, Jiahong Li¹, Kaiyu Wang¹, Gang Xu¹, Shusheng Wen^1,2, Jimei Chen^1,2, Jian Zhuang^1,2, Haiyun Yuan^1,2,*, Xiaobing Liu^1,2,*

Congenital Heart Disease, Vol.20, No.3, pp. 357-368, 2025, DOI:10.32604/chd.2025.066817 - 11 July 2025

Abstract Background: Totally thoracoscopic surgery (TTS) and right lateral thoracotomy (RLT) are both extensively utilized in the surgical repair for atrial septal defect (ASD). However, RLT is generally considered in low-weight pediatric patients as a result of restricted surgical exposure. This study aims to introduce an RLT approach for ASD repair in adults and compare its clinical outcomes with TTS. Methods: We conducted a retrospective analysis of the clinical data of 23 adult patients who underwent ASD repair at Guangdong Provincial People’s Hospital between June and October 2024. Patients were divided into two groups based on the… More >

YOUSEF KATIB^1,*, NASSER MULLA²

Oncology Research, Vol.32, No.11, pp. 1803-1809, 2024, DOI:10.32604/or.2024.052358 - 16 October 2024

Abstract Background: Lung cancer (LC) is one of the most common neoplastic diseases and a leading cause of death in Saudi Arabia. Its incidence in Saudi Arabia has increased by more than 3% within two decades. Our study aimed to describe the epidemiological and genetic landscapes of LC in Al-Madinah city in Saudi Arabia. Methods: A retrospective analysis was conducted on the medical records of 65 patients diagnosed with lung cancer between 2015 and 2021 at a single medical oncology center in Al-Madinah city of Saudi Arabia. Results: The mean patients’ age was 59.2 years, with 50… More >

Koren Hyogene Kwag^1,*, Ibrahim Kak¹, Ying Li², Walid Khass¹, Alec McKechnie¹, Oksana Nulman¹, Brande Brown¹, Manoj Chhabra¹

Congenital Heart Disease, Vol.19, No.1, pp. 107-121, 2024, DOI:10.32604/chd.2024.045953 - 20 March 2024

Abstract Objective: Accurate measurement of QT interval, the ventricular action potential from depolarization to repolarization, is important for the early detection of Long QT syndrome. The most effective QT correction (QTc) formula has yet to be determined in the pediatric population, although it has intrinsically greater extremes in heart rate (HR) and is more susceptible to errors in measurement. The authors of this study compare six different QTc methods (Bazett, Fridericia, Framingham, Hodges, Rautaharju, and a computer algorithm utilizing the Bazett formula) for consistency against variations in HR and RR interval. Methods: Descriptive Retrospective Study. We… More >

GUSTAVO MARTÍN VILLOLDO¹, MARÍA TERESA POMBO², MARIANA ARIS³, JOAQUÍN CHEMI¹, PABLO MANDÓ³, SUPRIYA NAGARAJU⁴, JUAN CAMEAN¹, ADRIÁN BURIONI¹, DEBORAH EGEA¹, MORA AMAT⁵, JOSÉ LEÓN MELLADO³, JOSÉ MORDOH³, ALBERTO VILLARONGA¹, MARÍA MARCELA BARRIO^3,*

Oncology Research, Vol.31, No.2, pp. 207-220, 2023, DOI:10.32604/or.2023.028163 - 10 April 2023

Abstract Intravesical Bacillus Calmette Guerin (BCG) is the gold standard therapy for intermediate/high-risk nonmuscle invasive bladder cancer (NMIBC). However, the response rate is ~60%, and 50% of non-responders will progress to muscle-invasive disease. BCG induces massive local infiltration of inflammatory cells (Th1) and ultimately cytotoxic tumor elimination. We searched for predictive biomarker of BCG response by analyzing tumor-infiltrating lymphocyte (TIL) polarization in the tumor microenvironment (TME) in pre-treatment biopsies. Pre-treatment biopsies from patients with NMIBC who received adequate intravesical instillation of BCG (n = 32) were evaluated retrospectively by immunohistochemistry. TME polarization was assessed by quantifying… More > Graphic Abstract

Alain J. Poncelet^1,*, Maureen Peers de Nieuwburgh², Stéphane Moniotte², Geoffroy de Beco¹, Karlien Carbonez², Jean E. Rubay¹, Thierry Detaille³, Laurent Houtekie³, Mona Momeni⁴

Congenital Heart Disease, Vol.18, No.2, pp. 151-168, 2023, DOI:10.32604/chd.2023.022636 - 15 March 2023

Abstract Background: Most outcome studies in congenital cardiac surgery for “low weight” neonates include patients undergoing surgery without cardiopulmonary bypass (CPB). The primary objective of our study was to identify risk factors for in-hospital mortality in neonates weighing less than 3 Kg and undergoing surgery with CPB. In addition, we compared the effect of early surgery with CPB (before 37W-gestational age (GA)) for congenital heart disease to delayed surgery until a corrected GA of 37 weeks in an attempt to promote weight gain. Methods: Retrospective single-center study including all patients operated between 1997 and 2017. Uni- and… More >

Huihui Zhang, Jing Yan, Xiaoyong Ren, Ying Sheng, Zhenghui Wang, Jianmin Liang, Yan Yan, Yangyang Jia, Zhihui Li, Jin Hou^*

Oncologie, Vol.24, No.4, pp. 707-716, 2022, DOI:10.32604/oncologie.2022.027023 - 31 December 2022

Abstract Objective: To assess the efficacy and toxicity of nimotuzumab combined with neoadjuvant or induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). Methods: Patients received intravenous nimotuzumab (400 mg, weekly for 1–3 weeks) combined with chemotherapy (5-fluorouracil/paclitaxel/docetaxel + nedaplatin/cisplatin for 1–2 cycles), prior to definitive surgical resection, radiotherapy or other treatments. The primary endpoint was the objective response rate (ORR). The secondary endpoints were tumor downstaging, complete response rate (CRR), partial response rate (PRR), disease control rate (DCR), R0 resection rate, pathological complete response (pCR), larynx preservation rate, overall survival (OS), progression-free survival (PFS), and… More >